Consensus Definitive Healthcare Corp.

Equities

DH

US24477E1038

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.99 ^USD	+3.86%		-0.99%	-29.68%

Apr. 16	Definitive Healthcare Introduces Carevoyance Sales Enablement Solution for Medtech Industry	CI
Mar. 22	Definitive Healthcare Collaborating With VML Health on Key Opinion Leader Management Tool for Clients	MT

Evolution of the average Target Price on Definitive Healthcare Corp.

Price target over the last 5 years

History of analyst recommendation changes

9c46b.JFzsEvl6Z4m-uFjpapRTL6lKHKOCT8qBlel7taXMVjs.RhiudMAQAc321j69IeE1TPsYWujbKP3G0ppN-vWKNH8SC4t7rC5K3vL1FQ~d37bbd8934c1cd0490c868be8368e805

Analyst Recommendations on Definitive Healthcare Corp.

Deutsche Bank Adjusts Definitive Healthcare Price Target to $10 From $9, Maintains Hold Rating	Mar. 01	MT
Barclays Adjusts Price Target on Definitive Healthcare to $11 From $10, Maintains Equalweight Rating	Mar. 01	MT
Stifel Adjusts Definitive Healthcare's Price Target to $11 From $12, Keeps Buy Rating	Jan. 17	MT
Needham Downgrades Definitive Healthcare to Hold From Buy	Jan. 17	MT
Canaccord Genuity Downgrades Definitive Healthcare to Hold From Buy, Price Target is $10	Jan. 05	MT
Barclays Raises Definitive Healthcare Price Target to $10 From $7, Maintains Equal Weight Rating	Dec. 27	MT
Deutsche Bank Cuts Definitive Healthcare Price Target to $9 From $14, Maintains Hold rating	Nov. 06	MT
Morgan Stanley Lowers Price Target on Definitive Healthcare to $9.50 From $15.50, Maintains Overweight Rating	Nov. 03	MT
Goldman Sachs Adjusts Price Target on Definitive Healthcare to $10.50 From $17, Keeps Neutral Rating	23-08-15	MT
Credit Suisse Adjusts Price Target on Definitive Healthcare to $11 From $12, Keeps Neutral Rating	23-08-15	MT
Canaccord Genuity Adjusts Price Target on Definitive Healthcare to $12 From $13, Maintains Buy Rating	23-08-15	MT
Morgan Stanley Adjusts Price Target on Definitive Healthcare to $15.50 From $17, Maintains Overweight Rating	23-08-15	MT
BofA Adjusts Price Target on Definitive Healthcare to $10.50 From $12, Keeps Neutral Rating	23-08-15	MT
Baird Downgrades Definitive Healthcare to Neutral From Outperform, Price Target is $13	23-07-24	MT
Barclays Adjusts Price Target on Definitive Healthcare to $10 From $11, Maintains Equalweight Rating	23-05-08	MT
Credit Suisse Lowers Definitive Healthcare's Price Target to $12 From $15, Keeps Neutral Rating	23-05-05	MT
William Blair Reinstates Definitive Healthcare at Outperform Rating	23-04-19	MT
Morgan Stanley Adjusts Price Target on Definitive Healthcare to $17 From $18, Maintains Overweight Rating	23-02-28	MT
Credit Suisse Lowers Definitive Healthcare's PT to $15 From $19, Says Outlook Continues to be Weighed by Long Sales Cycles; Keeps Neutral Rating	23-02-24	MT
Morgan Stanley Adjusts Price Target on Definitive Healthcare to $18 From $21, Maintains Overweight Rating	23-01-06	MT
Goldman Sachs Cuts Price Target on Definitive Healthcare to $17 From $31, Maintains Neutral Rating	22-11-07	MT
Deutsche Bank Adjusts Definitive Healthcare Price Target to $14 From $26, Maintains Hold Rating	22-11-07	MT
Needham Adjusts Price Target on Definitive Healthcare to $15 From $32, Maintains Buy Rating	22-11-04	MT
Credit Suisse Cuts Definitive Healthcare's PT to $19 From $24, Says Macro Continues to Slow Decision Making; Keeps Neutral Rating	22-11-04	MT
Morgan Stanley Adjusts Price Target on Definitive Healthcare to $21 From $23, Maintains Overweight Rating	22-11-04	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.99 USD

Average target price

10.4 USD

Spread / Average Target

+48.78%

High Price Target

12 USD

Spread / Highest target

+71.67%

Low Price Target

9 USD

Spread / Lowest Target

+28.76%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Definitive Healthcare Corp.

Deutsche Bank Securities
Barclays
Stifel Nicolaus
Needham & Co.
Canaccord Genuity
Morgan Stanley
Goldman Sachs
Credit Suisse
BofA Securities
Baird
William Blair & Co.
JPMorgan Chase
Jefferies & Co.
Raymond James

Ratings for Definitive Healthcare Corp.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar